Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

DSpace Repository

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Author: Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor O.; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Wu, Sterling; Burgents, Joseph; Molife, L. Rhoda; Powles, Thomas
Tübinger Autor(en):
Bedke, Jens
Published in: Journal of Clinical Oncology (2023), Bd. 41, H. 17_SUPPL, S. LBA4501
Verlagsangabe: Philadelphia : Lippincott Williams & Wilkins
Language: English
Full text: http://dx.doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501
ISSN: 0732-183X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)